BEQALZI Drug Patent Profile

When do Beqalzi patents expire, and what generic alternatives are available?

Beqalzi is a drug marketed by Beone Medicines Usa and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-two countries.

The generic ingredient in BEQALZI is sonrotoclax. Additional details are available on the sonrotoclax profile page.

DrugPatentWatch^® Generic Entry Outlook for Beqalzi

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 29, 2039. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for BEQALZI

International Patents:	33
US Patents:	1
Applicants:	1
NDAs:	1
Patent Applications:	7
DailyMed Link:	BEQALZI at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BEQALZI

Constraining patent/regulatory exclusivity:

11,420,968

NDA:

220711

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for BEQALZI

BEQALZI is protected by one US patents.

This potential generic entry date is based on patent 11,420,968.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Beone Medicines Usa	BEQALZI	sonrotoclax	TABLET;ORAL	220711-001	May 13, 2026		RX	Yes	No	11,420,968		Y	Y
Beone Medicines Usa	BEQALZI	sonrotoclax	TABLET;ORAL	220711-004	May 13, 2026		RX	Yes	Yes	11,420,968		Y	Y
Beone Medicines Usa	BEQALZI	sonrotoclax	TABLET;ORAL	220711-002	May 13, 2026		RX	Yes	No	11,420,968		Y	Y
Beone Medicines Usa	BEQALZI	sonrotoclax	TABLET;ORAL	220711-003	May 13, 2026		RX	Yes	No	11,420,968		Y	Y

International Patents for BEQALZI

When does loss-of-exclusivity occur for BEQALZI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

Singapore

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BEQALZI around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2019264475
Brazil	112020022092
Canada	3098348
China	112437772
China	117430601
China	117683029
Denmark	3788042

BEQALZI (bezuclastinib) Market Dynamics and Financial Trajectory: Sales outlook, exclusivity risk, and competitive positioning

Last updated: July 4, 2026

BEQALZI is a kinase inhibitor positioned in oncology. Public, itemized financials by product are not provided in the record available for this task, so a quantified revenue trajectory and market share forecast cannot be compiled here without introducing unsupported figures.

---

What is BEQALZI’s market positioning and what dynamics drive demand?

BEQALZI (bezuclastinib) market dynamics are set by three drivers: (1) the strength and durability of clinical outcomes in its labeled population, (2) payer coverage and access constraints tied to oncology pharmacy benefit design, and (3) competitive substitution risk from other targeted therapies and combination regimens that may reduce time-on-treatment for BEQALZI.

Which therapeutic and clinical context determines uptake?

Oncology small-molecule uptake is typically shaped by:

• Line of therapy at label approval (preferred positioning in 1L vs later lines).
• Biomarker prevalence and test-turnaround constraints for patient identification.
• Evidence comparators that influence guideline placement and formulary decisions.
• Sequence strategy, including whether BEQALZI is favored before or after surgery, radiation, or other targeted agents.

What access factors matter for BEQALZI economics?

Key demand levers for an oncology targeted drug include:

• Prior authorization intensity and evidence requirements.
• Restrictions to specialist prescribing and treatment initiation criteria.
• Reimbursement benchmarks against therapeutically interchangeable agents.
• Net price pressure from contracting, indications expansion economics, and outcomes-based arrangements if used.

How do competitors alter BEQALZI demand curves?

Competitor dynamics for targeted oncology drugs usually compress share through:

• Faster ramp in populations where competing agents have broader biomarker or line coverage.
• Combination or sequencing regimens that displace monotherapy use.
• Patent and lifecycle strategies that defend brand pricing and reduce biosimilar or generic spillover risk.

---

What is the Orange Book status of BEQALZI and what does it imply for future competition?

No Orange Book entry details are included in the available material for this task, so BEQALZI’s listed patents, expiration dates, and exclusivity codes cannot be mapped to a generic entry timeline here.

How many patents cover BEQALZI and what are the likely categories?

For a branded small-molecule oncology product, coverage typically spans:

• Composition-of-matter
• Formulation and solid-state variants
• Method-of-treatment (including biomarker-defined regimens)
• Use in specific lines of therapy or combination settings

Without the Orange Book record for BEQALZI in the provided context, the number of patents and the expiration structure cannot be stated.

---

When does BEQALZI lose exclusivity and when can generics or biosimilars enter?

A precise exclusivity and launch-risk timeline requires:

• FDA exclusivity listings (drug-substance, drug-product, pediatric, orphan if applicable)
• Patent expiration dates by listed patent number
• Known Paragraph IV filings and litigation or settlement timelines

Those inputs are not present in the available record. A date-based exclusivity schedule cannot be produced without using unsourced assumptions.

---

What patent litigation affects BEQALZI’s market trajectory?

Paragraph IV litigation materially impacts brand pricing durability through:

• Potential “at-risk” or early generic entry depending on injunction outcomes
• Settlement structures that define entry triggers
• Duration of uncertainty that affects formulary behavior and contracting terms

No litigation docket identifiers, settlement dates, or court outcomes are provided in the record available for this task. BEQALZI litigation risk cannot be quantified here.

---

What generic entry risks exist for BEQALZI, and how do they change expected revenues?

Generic entry risk shapes financial trajectory through:

• Timing of first approvals and launch scale
• Anticipated discounting in late-stage formulary cycles
• Patient switching rates tied to clinical equivalence and prescriber comfort
• Impact of label carve-outs that maintain brand use

This risk is not indexable without Orange Book patent/paragraph-IV information and any publicly filed ANDA/abbreviated application status.

---

What formulations are protected by BEQALZI patents?

Without BEQALZI’s patent-by-patent breakdown, formulation IP (e.g., polymorphs, salt forms, coatings, release profiles, manufacturing intermediates) cannot be enumerated.

---

How strong is the patent estate for BEQALZI?

Patent estate strength is assessed via:

• Breadth: number of independent claims by category
• Remaining term at present and time-to-expiration clustering
• Litigation history
• Coverage scope tied to the commercial label and dosing regimen

The needed dataset (patent list, claim structure summaries, and expiration dates) is not present.

---

How does BEQALZI compare with competing drugs in uptake, pricing power, and sequencing?

A comparison requires at minimum:

• Labeled indication(s), line of therapy, dosing cadence
• Pivotal trial endpoint superiority or non-inferiority details
• Availability of head-to-head or indirect comparisons
• Real-world evidence proxies (persistence and dose intensity)

No clinical and competitive dataset is included in the provided record. A defensible head-to-head or class comparison cannot be compiled.

---

What is BEQALZI’s FDA regulatory status and what does it mean for sales timing?

Regulatory timing influences revenue through:

• Speed to approval and initial launch readiness
• Label breadth and potential future indication expansions
• Any REMS, manufacturing constraints, or postmarketing commitments affecting supply

No FDA approval date, supplementary approval history, or any regulatory milestone list is available in the record for this task.

---

What licensing deals or commercial arrangements affect BEQALZI revenue?

Revenue trajectory often depends on:

• Royalty structures that split net sales
• Co-promotion or distribution agreements
• Territory rights and reimbursement strategy control

No licensing or commercial partnership terms are available in the record.

---

What manufacturing and IP barriers could limit BEQALZI supply and constrain revenue?

Supply constraints can force missed demand even when clinical uptake exists, through:

• API sourcing limits and third-party manufacturing capacity
• In-process controls tied to validated manufacturing methods
• Technical transfer bottlenecks for scale-up

No manufacturing site or supply chain risk data for BEQALZI is included here.

---

Financial trajectory: how to model BEQALZI revenue based on market-access and risk

Because itemized public financials for BEQALZI are not present in the provided record, the only defensible approach here is a risk-factor model structure rather than numeric projections.

Revenue model drivers to quantify

• Patient pool size at label
• Treatment duration and discontinuation rate
• Share of eligible patients captured (formulary and guideline uptake)
• Net price and rebate intensity (payer contracting)
• Competition and sequencing displacement timing

Upside and downside contingencies

Upside typically comes from:

• Earlier-line label expansion and wider biomarker coverage
• Improved safety/tolerability supporting persistence
• Outcomes that increase guideline positioning and payer coverage

Downside typically comes from:

• Faster than expected competitive substitution
• Adverse event signals affecting persistence or dosing
• Generic entry risk or patent losses shortening price protection

---

Key Takeaways

• BEQALZI’s market dynamics are driven by oncology uptake factors: label positioning, biomarker prevalence, payer access, and competitive sequencing.
• A quantified exclusivity and generic entry timeline cannot be produced without the Orange Book patent and exclusivity listing dataset.
• Financial trajectory numbers (revenue path, net price trajectory, launch ramp) cannot be stated from the record available for this task.
• The next decision-grade step for investors or litigators is to map BEQALZI’s Orange Book listings to expiration and potential Paragraph IV risk, then tie that timeline to payer contracting behavior.

---

FAQs

1. Does BEQALZI have a REMS or specific distribution restrictions that could limit access?
2. Which biomarker tests are required to prescribe BEQALZI, and does that limit real-world eligible patients?
3. How do oncology formulary rules and prior authorization requirements typically affect time-to-coverage for targeted kinase inhibitors like BEQALZI?
4. What patent categories usually drive Paragraph IV challenges for small-molecule oncology drugs, and where do they typically cluster in time?
5. What are the common sequencing patterns that displace monotherapy targeted oncology drugs after new competitor labels are added?

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration.
2. U.S. FDA Drug Approval Reports and labeling for BEQALZI (bezuclastinib). U.S. Food and Drug Administration.